Cargando…
Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020
BACKGROUND: Novel anticancer agents are initially evaluated in a palliative setting in phase I studies. The benefit–risk applying the selected dose from these phase I studies can be considered acceptable at time of registration, however, it is unknown if the optimal dose has been selected during dru...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586755/ https://www.ncbi.nlm.nih.gov/pubmed/34752995 http://dx.doi.org/10.1016/j.esmoop.2021.100301 |